Increasing amount of R&D expenditure by the major players and development of novel assay kits are expected to provide potential growth platform for adoption of qPCR instruments for diagnostic use.
Growing prevalence of cancer and other chronic diseases is anticipated to be the key driver for the industry growth. Moreover, growing geriatric population base in EU-28 countries is expected to increase age-related conditions such as diabetes and cardiovascular disorders.
Browse Detail Report With TOC @
Furthermore, major pharmaceutical companies are entering into collaborations with diagnostic instrument development companies through mergers and acquisitions or co-product development activities. For instance, in 2011, Life Technologies signed an agreement with GSK Biologicals to develop a companion diagnostic test. Life Technology will develop a qPCR based diagnostic assay for GSK’s MEGA-A3 cancer immunotherapy.
Further key findings from the study suggest:
Thermo Fisher/ABI dominated the market with a revenue share of over 38% in 2014 owing to high installed base of instruments such as StepOne, 7500, ViiA 7, and QuantStudio from ABI
Bio-Rad qPCR instruments market is the second largest in terms of revenue share over USD 7.0 million in 2014. Presence of licensing agreement with companies such as Mobidiag in Europe for the distribution Bio-Rad qPCR instruments, availability of user-friendly software and good technical support are some factors attributing for its high market coverage.
Thermo Fischer Scientific, Roche, Bio-Rad, and Qiagen accounted for over 84% of market share in 2014. Product development and distribution agreements are the key strategies adopted by the company for its growth. Whereas, the four countries namely UK, Germany, Spain and France covered around 56% of the total European market for qPCR used as IVD platform in 2014.
Browse Few “Healthcare” Market Research Reports
Global Allergic Rhinitis Drugs Market 2016-2020 @
Healthcare Payer BPO Market @
Global Bone Cement Industry 2016 @
Glucose Biosensor Market 2022 @
Germany dominated the European market with revenue of around USD 9.5 million in 2014. It is estimated to be one of the major countries for use of In-Vitro Diagnostics (IVD) platform in Europe.
The UK is expected to witness significant growth with a CAGR of around 13% over the forecast period owing to rising prevalence of target diseases and introduction of new automated technologies.
Countries such as France and Spain are experiencing economic growth over the past few years; these countries are expected to offer immense potential for Europe real time PCR industry mainly due to growing economy and high unmet needs
Market participants are constantly engaged in the introduction of technological advancements. The real time PCR instruments market involves extensive technological advancements to match user requirements.
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Address:Felton Office Plaza, 6265 Highway 9
Country: United States